EGFR and lung adenocarcinoma: Interestingly, the frequency of activating EGFR mutations, detected in 3/175 (1.7%) patients is much lower than in other subtypes of NSCLC, e.g., adenocarcinoma of the lung (ACA) with an incidence of 12.7% reported in our previous work [54].